About Neurimmune

Neurimmune Therapeutics AG is a Swiss biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products derived from human populations with unusual capacity to successfully fight a severe disease.

Based on novel scientific concepts developed at the University of Zurich, Neurimmune has established a unique technology platform – Reverse Translational Medicine (RTM™) – that supports Neurimmune’s translational research-focused drug discovery programs. The RTM™ platform provides a powerful resource for the rapid identification of human antibodies that do not require further optimization and can be channeled directly into the company’s drug discovery pipeline. These human antibodies display an excellent safety and efficacy profile with significantly increased probability of successfully reaching clinical proof of concept.

Neurimmune’s business strategy focuses on the discovery and development of human-derived antibodies through RTM™ at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing. In November 2007 Neurimmune entered into an agreement with Biogen Idec Inc., a leading biopharmaceutical company to develop and commercialize novel treatments for Alzheimer’s disease. In addition, Neurimmune Therapeutics is currently advancing a number of its RTM™ therapeutic antibody candidates through preclinical development.